Get the app
US › Healthcare

Kalaris Therapeutics, Inc. (KLRS)

US · Healthcare · Biotechnology

$2.00-8.68%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-11.5M
EPS
$-0.48
EPS estimate
$-0.50

EPS came in at -0.48 against a street estimate of -0.50 — a beat of 4.0%.

Key statistics

Market cap
$56.2M
Forward P/E
0.0
P/B
1.31
Book value
$2.42
EPS (TTM)
$-2.02
52-week high
$11.88
52-week low
$2.35
50-day MA
$3.55
200-day MA
$5.92

Analyst view

Analysts rate Kalaris Therapeutics, Inc. a strong buy (7 buy, 1 hold, 0 sell out of 8) with an average price target of $18.71.

Shareholding

Insiders
8.81%
Institutions
75.84%

Largest institutional holders

FundStake
Samsara BioCapital, LLC54.11%
RTW INVESTMENTS, LLC5.46%
Alyeska Investment Group, L.P.2.41%
Siren, L.L.C.1.83%
Vanguard Capital Management, LLC1.67%
Ikarian Capital, LLC1.51%
UBS Group AG1.10%
Renaissance Technologies Corp0.63%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Kalaris Therapeutics, Inc. — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-19.